Malignant lymphoma after diphenylhydantoin (dilantin) therapy

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Diphenylhydantoin (Dilantin) is a medication with a history of use in treating various conditions.
• Concerns have been raised regarding potential long-term side effects of diphenylhydantoin therapy.

Purpose of the Study:

• To investigate the potential association between prolonged diphenylhydantoin therapy and the risk of developing malignant lymphomas.
• To compare the incidence of lymphomas in patients treated with diphenylhydantoin to control groups.

Main Methods:

• Retrospective analysis of patient data.
• Comparison of lymphoma incidence in patients with Hodgkin's disease or non-Hodgkin's lymphoma, other cancers, and tumor-free individuals with a history of diphenylhydantoin use.

Main Results:

• A higher prevalence of diphenylhydantoin therapy was observed in patients with malignant lymphomas (1.6%) compared to those with other cancers (0.6%) and tumor-free individuals (0.4%).
• These findings suggest a potential, albeit small, excess risk of malignant lymphomas associated with long-term diphenylhydantoin treatment.

Conclusions:

• Long-term diphenylhydantoin therapy may be associated with a slightly increased risk of malignant lymphomas.
• The immunosuppressive properties of diphenylhydantoin could play a role in the development of these cancers.